BioArctic: CFO Anders Martin-Löf presenterar på Redeyes Temaevent: Alzheimer & Parkinsons April 8, 2025 Read more
Lecanemab demonstrates highly selective binding to a-beta protofibrils isolated from Alzheimer’s disease brains – Poster at ADPD 2025 April 7, 2025 Read more
BioArctic’s partner Eisai presented results of lecanemab Phase 3 confirmatory Clarity AD study for Early Alzheimer’s disease at CTAD conference November 30, 2022 Read more
Latest data on lecanemab presented at Alzheimer’s Association International Conference (AAIC) August 5, 2022 Read more
BioArctic and Eisai presented latest data regarding lecanemab at the AD/PDTM 2022 conference 18 mars, 2022 Read more
International Congress of Parkinsons disease and movement disorders® (MDS) September 20, 2021 Read more
Eisai presented latest data regarding drug candidate Lecanemab back-up at CTAD 2020 November 9, 2020 Read more
11th Annual European Life Sciences CEO Forum & Exhibition for Partnering & Investing in Biotech & Pharma Industry, Zurich, Switzerland February 26, 2018 Read more
